Full Papers
Perceived dyscognition reported by patients with fibromyalgia
S.J. Mcallister1, L.L. Toussaint2, D.A. Williams3, T.L. Hoskin4, M.O. Whipple5, A. Vincent6
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Psychology, Luther College, Decorah, Iowa, USA.
- Chronic Pain and Fatigue Research Center, University of Michigan Health System, Ann Arbor, Michigan, USA.
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. vincent.ann@mayo.edu
CER8679
2016 Vol.34, N°2 ,Suppl.96
PI 0048, PF 0054
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 26941074 [PubMed]
Received: 09/06/2015
Accepted : 04/09/2015
In Press: 26/02/2016
Published: 06/05/2016
Abstract
OBJECTIVES:
Patients with fibromyalgia often report dyscognition as a symptom; however, the literature on this symptom is sparse. Our objective for this cross-sectional study was to characterize dyscognition among patients with fibromyalgia, identify comorbid symptoms associated with dyscognition, and evaluate its relation with fibromyalgia severity.
METHODS:
Dyscognition was assessed with the Multiple Abilities Self-report Questionnaire (MASQ) for 681 patients with fibromyalgia. Other assessed comorbid symptoms were pain, fatigue, sleep problems, mood, physical and mental health, and autonomic function. Correlation and regression modeling were used to identify relations between the MASQ subscales and other fibromyalgia symptoms. Mixed analysis of variance was used to examine the profile of dyscognition in different levels of fibromyalgia. MASQ subscale scores from a previously described healthy normal control population were used for comparison.
RESULTS:
The mean (SD) age of the study patients was 55.8 (12.6) years, and most patients were female (93%) and white (91%). Perceived dyscognition was most related to depression, anxiety, and autonomic function. Across all fibromyalgia severity levels, patients had significantly higher levels of perceived dyscognition than the healthy controls. Significant differences existed for the MASQ total and most MASQ subscales among patients with mild, moderate, and severe fibromyalgia.
CONCLUSIONS:
Our study results provide further evidence that perceived dyscognition in fibromyalgia is influenced by various comorbid symptoms. In treating patients with fibromyalgia who have dyscognition, clinicians should consider the multiple types of dyscognition and the effects of other fibromyalgia symptoms.